Source Data Verification (SDV)
See the following -
Benefits, Challenges and Best Practices of Clinical Trials: Paper vs. Electronic Data Capture
On February 25th 2015, Clinovo hosted the 10th Session of the Silicon Valley BioTalks at HP’s headquarters in Palo Alto. The attendees consisted of life science industry professionals with the sole intent of discussing the benefits, challenges and best practices of paper-based clinical studies vs EDC based studies. To add a valuable experience to the conversation, the event featured a panel of 4 clinical trials professionals... Read More »
- Login to post comments
TransCelerate BioPharma Inc. Publishes Risk-Based Monitoring Recommendations For Central Monitoring And Technology Considerations
TransCelerate BioPharma Inc. ("TransCelerate") announced today the publication of its two most recent manuscripts on risk-based site monitoring ("Risk-Based Monitoring" or "RBM"), developed jointly by its 19 member companies. Both manuscripts have been accepted and published through the Drug Information Association's Therapeutic Innovation & Regulatory Science journal...
- Login to post comments
TransCelerate Shares Its Take On Risk-Based Monitoring Models And Tech
With clinical trial sponsors spending a sizable chunk of their huge Phase III trial budgets on source data verification (SDV) in return for questionable benefits, risk-based monitoring is an obvious target for TransCelerate BioPharma's R&D efficiency agenda. The Big Pharma consortium has further clarified its thinking on the topic in two research papers...
- Login to post comments